Softgel Source, LLC (SGS) announced its 2026 program for rapid turnaround of low volume, custom ingestible softgels, offering production priority and no minimum order quantity (MOQ) to facilitate product testing. The program aims to support U.S. biotech and pharmaceutical businesses in developing and testing new softgel products and formulations domestically.
“U.S. companies are at a crossroads, facing both the challenge and opportunity of bringing manufacturing back home,” said Kevin McDowell, Founder and CEO of Softgel Source, LLC. “By having our headquarters in Portland, Oregon USA, we’re well-positioned to help U.S. biotech and pharmaceutical businesses rapidly develop and test new and improved softgel products and formulations, creating a stronger competitive edge in their product marketplace.”
The company’s move to expand fast turnaround operations reflects a nationwide surge in U.S. manufacturing. A study from Deloitte and The Manufacturing Institute projects continued U.S. manufacturing job growth within this decade, requiring millions of new workers. Biotech and pharmaceutical manufacturing, in particular, are expected to grow 6–8% annually through 2030.
Businesses dependent on offshore manufacturing face disrupted international supply chains, long lead times, poor customer service, and shifting tariffs. Manufacturers that invest now in rapidly developing and testing new products domestically will be best positioned to diversify and thrive. “Located in the Pacific Northwest, SGS is ideally positioned to help companies address these offshore manufacturing issues,” McDowell continued. “We help companies rapidly test, scale and adapt by offering U.S.-manufactured softgels that meet the highest standards of quality and compliance at fast turnaround rates. From biotech labs to innovative nutritional supplements, the company delivers solutions that enable efficiency, consistency, and growth. We’re also an excellent choice for backup production when offshore sources falter.”
Constant regulatory changes have potentially disruptive implications for U.S. softgel suppliers. Many products will need to be reformulated and retested on short notice. “Continuous changes in U.S. and international regulations mean that many companies with softgel products affected by those changes need a way to rapidly test new products and formulations and get updated products into production fast,” McDowell added. “A local U.S. based manufacturer like SGS with fast turnaround and low MOQ is ideal for companies dealing with those types of time sensitive reformulation and testing requirements.”
Softgel Source is a boutique manufacturer of custom ingestible softgels for the vitamin, medication, supplement, and pet product industries. Located in Portland, Oregon, SGS focuses on high touch custom softgel manufacturing for U.S. clients. For more information, visit Softgel Source.
